Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications.
The understanding of immunological processes associated with allergic diseases and advancements in antibody bioengineering has driven the development of specific biological therapies. Monoclonal antibodies, selectively targeting cytokines involved in the pathogenesis of allergic processes or their r...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2024
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/44413 |
| Aporte de: |
| id |
I10-R327-article-44413 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
immunoglobulins hypersensitivity asthma allergic rhinitis pharmacology inmunoglobulinas alergia asma rinitis alérgica farmacología imunoglobulinas hipersensibilidade asma rinite alérgica farmacologia |
| spellingShingle |
immunoglobulins hypersensitivity asthma allergic rhinitis pharmacology inmunoglobulinas alergia asma rinitis alérgica farmacología imunoglobulinas hipersensibilidade asma rinite alérgica farmacologia Pury, Selene Saranz, Ricardo José Irastorza, María José Sasia, Laura Veronica Visconti, Pilar Alegre, Graciela Lozano, Natalia Andrea Berardi, Yanina Viviana Lozano, Alejandro ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. |
| topic_facet |
immunoglobulins hypersensitivity asthma allergic rhinitis pharmacology inmunoglobulinas alergia asma rinitis alérgica farmacología imunoglobulinas hipersensibilidade asma rinite alérgica farmacologia |
| author |
Pury, Selene Saranz, Ricardo José Irastorza, María José Sasia, Laura Veronica Visconti, Pilar Alegre, Graciela Lozano, Natalia Andrea Berardi, Yanina Viviana Lozano, Alejandro ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . |
| author_facet |
Pury, Selene Saranz, Ricardo José Irastorza, María José Sasia, Laura Veronica Visconti, Pilar Alegre, Graciela Lozano, Natalia Andrea Berardi, Yanina Viviana Lozano, Alejandro ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . |
| author_sort |
Pury, Selene |
| title |
Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. |
| title_short |
Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. |
| title_full |
Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. |
| title_fullStr |
Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. |
| title_full_unstemmed |
Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. |
| title_sort |
monoclonal antibodies in allergic diseases: development, pharmacology, and clinical applications. |
| description |
The understanding of immunological processes associated with allergic diseases and advancements in antibody bioengineering has driven the development of specific biological therapies. Monoclonal antibodies, selectively targeting cytokines involved in the pathogenesis of allergic processes or their receptors, have emerged as a promising tool in treating various conditions, including asthma, allergic rhinitis, urticaria, and severe atopic dermatitis. Since the approval of the first anti-CD3 mouse monoclonal antibody in 1986, remarkable progress has been achieved, marked by the development of chimeric, 'humanized,' and 'fully human' antibodies. The 'humanization' of monoclonal antibodies has played a crucial role in reducing the risk of immunogenicity and minimizing adverse effects, thereby notably enhancing the safety and efficacy of these therapeutic interventions.
The aim of this article is to address the characterization, development, pharmacokinetics, pharmacodynamics, and clinical utility of monoclonal antibodies, with a primary focus on allergic diseases. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2024 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/44413 |
| work_keys_str_mv |
AT puryselene monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT saranzricardojose monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT irastorzamariajose monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT sasialauraveronica monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT viscontipilar monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT alegregraciela monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT lozanonataliaandrea monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT berardiyaninaviviana monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT lozanoalejandro monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT monoclonalantibodiesinallergicdiseasesdevelopmentpharmacologyandclinicalapplications AT puryselene anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT saranzricardojose anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT irastorzamariajose anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT sasialauraveronica anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT viscontipilar anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT alegregraciela anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT lozanonataliaandrea anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT berardiyaninaviviana anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT lozanoalejandro anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT anticuerposmonoclonalesenenfermedadesalergicasdesarrollofarmacologiayaplicacionesclinicas AT puryselene anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT saranzricardojose anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT irastorzamariajose anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT sasialauraveronica anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT viscontipilar anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT alegregraciela anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT lozanonataliaandrea anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT berardiyaninaviviana anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT lozanoalejandro anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas AT anticorposmonoclonaisemdoencasalergicasdesenvolvimentofarmacologiaeaplicacoesclinicas |
| first_indexed |
2025-02-05T22:05:33Z |
| last_indexed |
2025-02-05T22:05:33Z |
| _version_ |
1823256749001408512 |
| spelling |
I10-R327-article-444132024-12-18T15:34:14Z Monoclonal Antibodies in Allergic Diseases: Development, Pharmacology, and Clinical Applications. Anticuerpos monoclonales en enfermedades alérgicas: Desarrollo, farmacología y aplicaciones clínicas Anticorpos monoclonais em doenças alérgicas: Desenvolvimento, farmacologia e aplicações clínicas. Pury, Selene Saranz, Ricardo José Irastorza, María José Sasia, Laura Veronica Visconti, Pilar Alegre, Graciela Lozano, Natalia Andrea Berardi, Yanina Viviana Lozano, Alejandro ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . ., . immunoglobulins hypersensitivity asthma allergic rhinitis pharmacology inmunoglobulinas alergia asma rinitis alérgica farmacología imunoglobulinas hipersensibilidade asma rinite alérgica farmacologia The understanding of immunological processes associated with allergic diseases and advancements in antibody bioengineering has driven the development of specific biological therapies. Monoclonal antibodies, selectively targeting cytokines involved in the pathogenesis of allergic processes or their receptors, have emerged as a promising tool in treating various conditions, including asthma, allergic rhinitis, urticaria, and severe atopic dermatitis. Since the approval of the first anti-CD3 mouse monoclonal antibody in 1986, remarkable progress has been achieved, marked by the development of chimeric, 'humanized,' and 'fully human' antibodies. The 'humanization' of monoclonal antibodies has played a crucial role in reducing the risk of immunogenicity and minimizing adverse effects, thereby notably enhancing the safety and efficacy of these therapeutic interventions. The aim of this article is to address the characterization, development, pharmacokinetics, pharmacodynamics, and clinical utility of monoclonal antibodies, with a primary focus on allergic diseases. El avance en la comprensión de los procesos inmunológicos relacionados con enfermedades alérgicas y en la bioingeniería de anticuerpos ha propiciado el desarrollo de terapias biológicas específicas. Los anticuerpos monoclonales, dirigidos selectivamente hacia citocinas involucradas en la patogénesis de los procesos alérgicos, o sus receptores, han emergido como una herramienta prometedora en el tratamiento de diversas afecciones, tales como el asma, la rinitis alérgica, la urticaria y la dermatitis atópica grave. Desde la aprobación del primer anticuerpo monoclonal anti-CD3 de origen murino en 1986, se ha transitado un largo recorrido, caracterizado por la aparición de anticuerpos quiméricos, los que por estructura molecular de la inmunoglobulina es semejante a los del ser humano denominados “humanizados” y los exactamente iguales llamados “completamente humanos”. La “humanización” de los anticuerpos monoclonales ha contribuido significativamente a reducir tanto el riesgo de inmunogenicidad como la incidencia de efectos adversos, mejorando notablemente la seguridad y eficacia de estas terapias. Este artículo tiene como objetivo abordar la caracterización, desarrollo, farmacocinética, farmacodinamia y utilidad clínica de los anticuerpos monoclonales, principalmente focalizados en las enfermedades alérgicas. O avanço na compreensão dos processos imunológicos relacionados a doenças alérgicas e na bioengenharia de anticorpos tem impulsionado o desenvolvimento de terapias biológicas específicas. Os anticorpos monoclonais, direcionados seletivamente para citocinas envolvidas na patogênese de processos alérgicos ou seus receptores, emergiram como uma ferramenta promissora no tratamento de diversas condições, incluindo asma, rinite alérgica, urticária e dermatite atópica grave. Desde a aprovação do primeiro anticorpo monoclonal murino anti-CD3 em 1986, notáveis avanços foram alcançados, marcados pelo desenvolvimento de anticorpos quiméricos, "humanizados" e "totalmente humanos". A "humanização" dos anticorpos monoclonais desempenhou um papel crucial na redução do risco de imunogenicidade e na minimização de efeitos adversos, aumentando significativamente a segurança e eficácia dessas intervenções terapêuticas. O objetivo deste artigo é abordar a caracterização, desenvolvimento, farmacocinética, farmacodinâmica e utilidade clínica de anticorpos monoclonais, com foco principal em doenças alérgicas. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2024-12-13 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion application/pdf text/html https://revistas.unc.edu.ar/index.php/med/article/view/44413 10.31053/1853.0605.v81.n4.44413 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 81 No. 4 (2024); 804-823 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 81 Núm. 4 (2024); 804-823 Revista da Faculdade de Ciências Médicas de Córdoba; v. 81 n. 4 (2024); 804-823 1853-0605 0014-6722 10.31053/1853.0605.v81.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/44413/47625 https://revistas.unc.edu.ar/index.php/med/article/view/44413/47857 Derechos de autor 2024 Universidad Nacional de Córdoba https://creativecommons.org/licenses/by-nc/4.0 |